0000000000267035

AUTHOR

Katrien Swerts

showing 2 related works from this author

Influence of Neuroblastoma Stage on Serum-Based Detection of MYCN Amplification

2009

BACKGROUND: MYCN oncogene amplification has been defined as the most important prognostic factor for neuroblastoma (NB), the most common solid extracranial neoplasm in children. High copy numbers are strongly associated with rapid tumor progression and poor outcome, independently of tumor stage or patient age, and this has become an important factor in treatment stratification. PROCEDURE: By real-time quantitative PCR analysis, we evaluated the clinical relevance of circulating MYCN DNA of 267 patients with locoregional or metastatic NB in children less than 18 months of age. RESULTS: For patients in this age group with INSS stage 4 or 4S NB and stage 3 patients, serum-based determination o…

Neuroblastoma stageGenes mycArticleNeuroblastomaPatient ageNeuroblastomaGene duplicationmedicineNeoplasmHumansChildneoplasmsRetrospective StudiesNeoplasm Stagingbusiness.industryGene AmplificationChild; DNA Neoplasm/blood; Gene Amplification; Genes myc; Humans; Neoplasm Staging; Neuroblastoma/genetics; Neuroblastoma/pathology; Retrospective StudiesRetrospective cohort studyHematologyDNA Neoplasmmedicine.diseaseOncologyTumor progressionPediatrics Perinatology and Child HealthMycn amplificationCancer researchbusiness
researchProduct

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

2009

Summary Background More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings The signature has a performance, s…

OncologyPediatricsmedicine.medical_specialtyMultivariate analysisbusiness.industryCase-control studyOdds ratiomedicine.diseaseBreast cancerOncologyNeuroblastomaInternal medicinemedicineStage (cooking)businessProspective cohort studySurvival analysisThe Lancet Oncology
researchProduct